IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

ABSTRACT: Graft-versus-host disease (GvHD) remains a major cause of transplant-related mortality. Interleukin-2 (IL-2) plus sirolimus (SIR) synergistically reduces acute GvHD in rodents and promotes regulatory T cells. This phase II trial tested the hypothesis that IL-2 would facilitate STAT5 phosphorylation in donor T cells, expand regulatory T cells, and ameliorate GvHD. Between 16^th April 2014 and 19^th December 2015, 20 patients received IL-2 (200,000 IU/m² thrice weekly, days 0 to +90) with SIR (5-14 ng/mL) and tacrolimus (TAC) (3-7 ng/mL) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation (HCT). The study was designed to capture an increase in regulatory T cells from 16.0% to more than 23.2% at day +30. IL-2/SIR/TAC signi

SUBMITTER: Betts BC 

PROVIDER: S-EPMC5477614 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature